Microbiome Modulator

Akkermansia muciniphila

Akkermansia muciniphila

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

~1 × 10^10 cells/day (reported in human studies)

watchEffect Window

Observed effects generally after 12-week intervention windows in human trials.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Akkermansia muciniphila is a gut associated microbe or microbial product used to influence microbiome composition and metabolite production. It is taken to support digestion, barrier function, and immune signaling.

Human evidence is still product-specific and mostly centered on metabolic health rather than general digestive wellness. The clearest signal comes from pasteurized or proprietary preparations studied in overweight, insulin-resistant, or type 2 diabetes populations, where insulin sensitivity and some cardiometabolic markers may improve. Benefits appear to depend on baseline microbiome state, and generalized probiotic claims are not justified from the current Akkermansia literature.

Microbiome modulation with effects on gut barrier/inflammation and metabolic signaling, with strongest human data in insulin resistance contexts.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Improved insulin sensitivity and reduced insulinemia in controlled overweight/obese RCT context
  • Potential body composition and HbA1c improvements in low-baseline *Akkermansia* subgroup

Secondary Outcomes

  • Selective knee extensor strength improvement in older adults at 12 weeks
  • Potential inflammatory/ gut-barrier modulation

Safety

Contraindications and Interactions

Contraindications

  • Pregnancy/lactation without clinician oversight
  • Severe immune compromise
  • History of serious unexplained immune-mediated intolerance to supplements

Side effects

  • Mild/transient GI discomfort (possible)
  • No major trial-reported safety signals
  • Uncertain rare immune-related events due limited evidence base

Interactions

  • Metformin-related glucose responses may overlap with existing glucose plans
  • Antibiotics/microbiome-altering drugs
  • Other probiotic stacks complicating attribution

Avoid if

  • Known active infection
  • Unstable medical conditions without clinician follow-up
  • Pregnancy/lactation

Evidence

Study-level References

akkermansia-muciniphila-SRC-001Randomized double-blind, placebo-controlled human pilot trial.
Sourceopen_in_new

Depommier C et al. Nat Med. 2019;25(7):1096-1103. PMID 31263284. DOI: 10.1038/s41591-019-0495-2.

Population: Overweight/obese insulin-resistant adults.

Dose protocol: Daily oral *A. muciniphila* 10^10/day (live or pasteurized) for 3 months.

Key findings: Improved insulin sensitivity (+28.6%), reduced insulinemia (-34.1%), and total cholesterol (-8.7%). Weight/fat effects were smaller and not consistently significant.

Notes: Small trial, proprietary interest, and funding relationships are present.

Paper content

Improved insulin sensitivity (+28.6%), reduced insulinemia (-34.1%), and total cholesterol (-8.7%); weight/fat effects were smaller and not consistently significant.

akkermansia-muciniphila-SRC-002Randomized, double-blind, placebo-controlled trial
Sourceopen_in_new

Zhang Y, Liu R, Chen Y, et al. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut. Cell Metab. 2025;37(3):592-605.e6. doi:10.1016/j.cmet.2024.12.010. PMID:39879980.

Population: Adults with overweight or obesity and type 2 diabetes receiving routine lifestyle guidance.

Dose protocol: AKK-WST01 daily for 12 weeks.

Key findings: Subgroup signal for reduced body weight, fat mass, and HbA1c in low-baseline participants.

Notes: Between-group null effects overall. Subgroup dependence on baseline microbiome state.

Paper content

This 12-week randomized, double-blind, placebo-controlled trial enrolled 58 participants with overweight or obese type 2 diabetes and tested AKK-WST01 versus placebo alongside routine lifestyle advice. The overall trial was between-group null for body weight and HbA1c, which is the main corrective point for the supplement entry. The signal emerged only after stratifying by baseline gut abundance. Participants with low baseline Akkermansia showed strong colonization plus significant reductions in body weight, fat mass, and HbA1c, while those with high baseline abundance showed poor colonization and no meaningful clinical improvement. The trial supports a responder-dependent, microbiome-guided framing rather than a broad glucose-control claim for all users.

akkermansia-muciniphila-SRC-003Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_new

Kang C-H et al. Nutrients. 2024;16(23):4037. DOI: 10.3390/nu16234037.

Population: Older adults ≥60 years (n=100 randomized).

Dose protocol: HB05P 1 × 10^10 cells/day for 12 weeks.

Key findings: Select improvements in left leg extensor peak torque and follistatin versus placebo.

Notes: Single trial and one product-specific postbiotic strain. Effect size is selective across endpoints. Performance outcomes were not broadly replicated.

Paper content

Select improvements in left leg extensor peak torque and follistatin versus placebo.

akkermansia-muciniphila-SRC-004Mouse mechanistic/preclinical study (not human efficacy).
Sourceopen_in_new

Zhu X et al. Microbiome. 2023;11:120. PMID 37254162. DOI: 10.1186/s40168-023-01567-1.

Population: Aged mice.

Dose protocol: Metformin-associated enrichment approach with *A. muciniphila* manipulation.

Key findings: Improved cognitive-like outcomes in mice, with reduced IL-6 signaling.

Notes: Translatability gap to human cognitive or work-performance outcomes.

Paper content

Improved cognitive-like outcomes in mice, with reduced IL-6 signaling.

Guides

Setup

Help